| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | IOX2 | GDSC1000 | pan-cancer | AAC | -0.14 | 7e-05 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.003 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.003 |
| mRNA | DBeQ | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | XAV-939 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.13 | 0.006 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | 0.087 | 0.006 |
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.006 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.095 | 0.007 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.15 | 0.008 |